Cellular Senescence Network (SenNet):Technology Projects (UG3/UH3 Clinical Trial Not Allowed)
This grant will fund projects to develop new technologies for identifying and targeting senescent cells in human tissues to better understand their role in health and disease and advance therapies.
Funder: National Institutes of Health (NIH)
Due Dates: December 9, 2025 (forecasted)
Funding Amounts: Estimated total funding $6,000,000; ~15 awards anticipated; UG3/UH3 activity code
Summary: Supports development of innovative tools and technologies to identify, characterize, and target senescent cell types in vivo to advance understanding of cellular senescence in health and disease.
Key Information: This is a forecasted opportunity; applications are not yet being accepted.
Description
The National Institutes of Health (NIH) will soon solicit applications for Stage 2 of the Cellular Senescence Network (SenNet) Program, specifically for Senescence Technology Projects (SenTecs). These projects aim to develop and advance novel tools and technologies that address the complexity of cellular senescence, enabling the identification, characterization, and targeting of senescent cell types ("senotypes") in vivo. The program’s broader goal is to improve understanding of the biological consequences of senescent cell heterogeneity in human health and disease, and to facilitate the development of new therapeutic strategies (senotherapeutics) that can improve health outcomes.
This Notice of Funding Opportunity (NOFO) is being provided in advance to allow researchers time to form collaborations and design projects. The funding mechanism will use the UG3/UH3 cooperative agreement activity code, supporting both initial and milestone-driven phases.
